U.S. markets close in 2 hours 14 minutes
  • S&P 500

    4,358.50
    -84.61 (-1.90%)
     
  • Dow 30

    34,323.36
    -546.01 (-1.57%)
     
  • Nasdaq

    14,591.94
    -378.03 (-2.53%)
     
  • Russell 2000

    2,245.32
    -35.69 (-1.56%)
     
  • Crude Oil

    75.13
    -0.32 (-0.42%)
     
  • Gold

    1,736.90
    -15.10 (-0.86%)
     
  • Silver

    22.49
    -0.20 (-0.90%)
     
  • EUR/USD

    1.1684
    -0.0018 (-0.15%)
     
  • 10-Yr Bond

    1.5250
    +0.0410 (+2.76%)
     
  • GBP/USD

    1.3532
    -0.0172 (-1.26%)
     
  • USD/JPY

    111.5200
    +0.5420 (+0.49%)
     
  • BTC-USD

    41,382.05
    -1,731.47 (-4.02%)
     
  • CMC Crypto 200

    1,020.74
    -36.40 (-3.44%)
     
  • FTSE 100

    7,028.10
    -35.30 (-0.50%)
     
  • Nikkei 225

    30,183.96
    -56.10 (-0.19%)
     

Merck Discloses New Islatravir Data Supporting Safety Profile For PrEP Regime For HIV Infection

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Merck & Co Inc (NYSE: MRK) has announced new data from Phase 2a trial evaluating islatravir for pre-exposure prophylaxis (PrEP) of HIV-1 infection in adults at low risk of contracting HIV-1.

  • After 24 weeks, once-monthly oral islatravir was generally well tolerated versus placebo.

  • Most adverse events (AEs) were mild, and there were no serious drug-related AEs in people who received islatravir.

  • The levels of islatravir in peripheral blood mononuclear cells (PBMCs) also remained above the pre-specified efficacy PK threshold for PrEP at both doses studied (60 mg and 120 mg) eight weeks after the last study dose.

  • These data were shared at the International AIDS Society Conference on HIV Science.

  • Islatravir (MK-8591) is an investigational nucleoside reverse transcriptase translocation inhibitor.

  • Price Action: MRK shares are up 0.14% at $77.16 during the premarket session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.